Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | QDPR | P09417 | 2/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2027017 | 0.90 | RAB9A (0.50) | SLC18A3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL15577442 | 0.90 | RAB9A (0.50) | SLC18A3NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL3080099 | 0.84 | QDPR (0.62) | SLC18A3KCNH2HRH3QDPRALDH1A1 | |
| SCHEMBL17398139 | 0.84 | ESR2 (0.55) | KCNH2HRH3QDPR | |
| SCHEMBL1531725 | 0.83 | KCNH2 (0.59) | SLC18A3CA12CA1CA2CA7 | |
| SCHEMBL3634211 | 0.83 | SLC18A3 (0.49) | SLC18A3QDPRBACE1ALDH1A1NAMPT | |
| SCHEMBL7371984 | 0.83 | PARP10 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19212189 | 0.82 | ALDH1A1 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL609605 | 0.82 | TRPC6 (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30783142 | 0.82 | TRPC6 (0.52) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113651799-A | Six-membered non-aromatic ring-containing diaryl pyrimidine HIV-1 reverse transcriptase inhibitor and preparation method and application thereof | 山东大学 | 2021-11-16 | — | — | CN | claimed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | claimed |
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240158418-A1 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | C4 THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024102849-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING 2,5-SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4351583-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 Therapeutics, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4347044-A2 | EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS | C4 Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20240076300-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | US | disclosed |
| WO-2023250029-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249968-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-DJPYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249970-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-1326519-C | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2007-07-18 | — | — | CN | disclosed |
| EP-1775298-A1 | THIENOPYRAZOLE DERIVATIVE HAVING PDE7 INHIBITORY ACTIVITY | Daiichi Asubio Pharma Co., Ltd. (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-7067534-B1 | Substituted anilinic piperidines as MCH selective antagonists | H. LUNDBECK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | disclosed |
| EP-1411942-A4 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2005-01-26 | — | — | EP | disclosed |
| EP-1411942-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | Synaptic Pharmaceutical Corporation (US) | 2004-04-28 | — | — | EP | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| WO-2003004027-A1 | SUBSTITUTED ANILINIC PIPERIDINES AS MCH SELECTIVE ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199581-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | BRAF, NRAS, KRAS | SLC18A3 4699/4885CA12 4238/4885CA1 4783/4885 |
| US-20240158418-A1 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | EGFR, ERBB2, ERBB3 | SLC18A3 3653/4885CA12 2452/4885CA1 3242/4885 |
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | SLC18A3 284/4885CA12 4588/4885CA1 4507/4885 |
| US-20240076300-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | SLC18A3 4637/4885CA12 4577/4885CA1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.